UK-based pharmaceuticals manufacturer, Dechra is poised to acquire Sydney-based Apex in a deal reportedly worth £31.3m.
The buyout includes the purchase of Apex’s manufacturing facility near Sydney. The buyout includes the purchase of Apex’s manufacturing facility and will provide Dechra with access to the Australian pharmaceuticals market, as well as opportunity to support growth in Asia. Founded in 1962, Apex is a veterinary pharmaceuticals company which creates and…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login